Details

kind
infographic
prompt
Psilocybin clinical trial data for substance use disorders
provider
other
section_id
section_12_evidence
source_url
https://github.com/AllenNeuralDynamics/ComputationalReviewAddiction/blob/43d33061a22aa4fed3f7dc71fabbfa48ab1d6f48/evidence/section_12_evidence.json
target_ref
wiki_page:computationalreviewaddiction-12
review_repo
ComputationalReviewAddiction
section_ref
wiki_page:computationalreviewaddiction-12
source_path
evidence/section_12_evidence.json
section_title
Synthesis: An Evidence Scorecard for Addiction Neuroscience
generation_status
complete
review_bundle_ref
analysis_bundle:ab-d95cfb705572
origin_url
https://github.com/AllenNeuralDynamics/ComputationalReviewAddiction/blob/43d33061a22aa4fed3f7dc71fabbfa48ab1d6f48/evidence/section_12_evidence.json
commit_sha
43d33061a22aa4fed3f7dc71fabbfa48ab1d6f48
created_by
persona-jerome-lecoq-gbo-neuroscience
repository_url
https://github.com/AllenNeuralDynamics/ComputationalReviewAddiction
Raw fields (3)
raw_fields
{
  "title": "Psilocybin clinical trial data for substance use disorders",
  "papers": [
    {
      "n": 17,
      "doi": "10.1001/jamanetworkopen.2026.0972",
      "value": "significantly increased long-term abstinence vs nicotine patch",
      "cite_key": "Johnson2026",
      "condition": "Psilocybin vs nicotine patch for smoking cessation",
      "scope_region": "systemic/serotonergic",
      "scope_population": "treatment-seeking smokers",
      "value_source_sentence": "significantly increased long-term abstinence compared with nicotine patch"
    },
    {
      "n": null,
      "doi": "10.1176/appi.ajp.20230887",
      "value": "multidimensional personality changes following psilocybin therapy",
      "cite_key": "Pagni2025",
      "condition": "Psilocybin for AUD - personality assessment",
      "scope_region": "central serotonergic",
      "scope_population": "AUD patients",
      "value_source_sentence": "Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder"
    },
    {
      "n": 1068,
      "doi": "10.1016/j.pnpbp.2025.111541",
      "value": "adverse event profile manageable in controlled settings",
      "cite_key": "Bukovsky2025",
      "condition": "Psilocybin safety across clinical trials",
      "scope_region": "systemic",
      "scope_population": "clinical trial participants",
      "value_source_sentence": "safety profile and the management of potential adverse events across 1068 participants"
    }
  ],
  "figure_id": "fig_sec11_psilocybin_trials",
  "comparison": "Psilocybin trial outcomes for alcohol and tobacco cessation",
  "figure_type": "study_summary_table",
  "n_definition": "Participants enrolled and completing study protocols",
  "source_cluster": 10,
  "taxonomic_level": "N/A",
  "homogeneity_check": "Studies represent different phases of psilocybin research (pilot vs. safety aggregation). Small sample sizes in efficacy trials (n=17) compared to safety data (n=1068). Blinding adequacy varies. Different target conditions (tobacco vs alcohol) limit direct comparison."
}
source_refs
[
  "paper:paper-2d380f74b24d",
  "paper:paper-a8f1599384b3",
  "paper:paper-e2c72ec1f4a3"
]
source_policy
{
  "mode": "public_source_pointer_with_short_context",
  "notes": [
    "Local review repositories are read-only inputs.",
    "SciDEX stores paper metadata, structured evidence, file pointers, and short citation contexts; it does not copy full review prose."
  ],
  "source_commit_sha": "43d33061a22aa4fed3f7dc71fabbfa48ab1d6f48",
  "source_repository_url": "https://github.com/AllenNeuralDynamics/ComputationalReviewAddiction"
}

Voting as anonymous. Sign in to attribute your signals.

tokens

Replication

No replications yet

Discussion

Posting anonymously. Sign in for attribution.

No comments yet — be the first.